Objective To explore a new method for the treatment of refractory recurrent liver cancer. Methods The treatment process and effect of a patient with refractory recurrent liver cancer who received complete remission (CR) treated with second-line targeted drug regorafenib combined with camrelizumab in the Department of Hepatobiliary and Pancreatic Surgery of Dongguan Hospital Affiliated to Southern Medical University were retrospectively analyzed and summarized. Results In the previous 3 years, the patient underwent radical ablation, resection of recurrent cancer in the middle lobe of the liver, ablation of recurrent cancer in S2 and S8 segments of the liver, and multidisciplinary treatment with the first-line targeted drug lenvatinib, extensive intrahepatic recurrence and metastasis still occurred. Finally, the patient was treated with the second-line targeted drug regorafenib combined with camrelizumab for systemic treatment. All the intrahepatic lesions were liquefied and necrotic, and most of them were significantly reduced or disappeared, AFP decreased from the highest peak of 20 867.00 μg/L to normal. The therapeutic effect of CR was evaluated and remained stable for more than 12 months. There were no obvious toxic and side effects. The patient had a good quality of life and insisted on working normally. Conclusion The second-line targeted drug regorafenib combined with new immunotherapy may still have curative effect on refractory recurrent liver cancer after various comprehensive treatment failures, and even obtain the hope and opportunity of long-term tumor-free survival.
ObjectiveTo summarize the comprehensive multidisciplinary team (MDT) treatment and holistic scientific management approach in a case of hepatocellular carcinoma (HCC) in S7+S9 segments with prostatic metastasis. MethodsA retrospective analysis was conducted on the clinical data and follow-up outcomes of a patient with HCC in S7+S9 segments who developed prostatic metastasis during treatment, admitted to the Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital of Guangdong Province). ResultsDue to the complexity of the patient’s condition, an MDT discussion was held upon initial admission. It was concluded that the HCC diagnosis was clear, with lesions confined to the liver (S7+S9 segments) and a tumor diameter less than 3 cm, making surgical resection or ablation therapy the preferred options. However, the patient declined liver transplantation and surgical resection. Therefore, CT-guided microwave ablation (MWA) was performed on the primary HCC lesions in segments S7 and S9b. Prior to subsequent treatments for recurrent disease, MDT discussions were held again, and treatments were tailored to the discussion outcomes while respecting the patient’s wishes. Over time, the patient underwent CT-guided liver puncture MWA, re-ablation for recurrent tumors, transarterial chemoembolization (TACE), stereotactic body radiation therapy (SBRT), targeted therapy, and immunotherapy. Following this comprehensive MDT treatment plan, the patient had survived for over 78 months, with no evidence of active tumor lesions in the liver, prostate, or other parts of the body. Alpha-fetoprotein levels and liver function remained normal, and the patient’s quality of life was good. ConclusionComprehensive MDT treatment incorporates various technologies and approaches, along with holistic scientific management, can yield favorable outcomes for patients with complex and challenging HCC.